Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Investing

5 Small Biotech ETFs to Watch

by November 29, 2023
November 29, 2023
5 Small Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

1. Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Company Profile

AUM: US$81.96 million

The Global X Genomics & Biotechnology ETF tracks genomic science stocks, such as companies focused on gene editing, genomic sequencing, genetic medicine and therapy, computational genomics and biotechnology. This fund was first introduced to the market in April 2019 and invests at least 68 percent of its assets in mid- and small-cap companies.

There are 42 holdings in this biotech fund. Its top holdings include CRISPR Therapeutics (NASDAQ:CRSP) with a weight of 4.81 percent; Veracyte (NASDAQ:VCYT), weighing in at 4.5 percent; and Qiagen (NYSE:QGEN) at a 4.42 percent weightage.

2. ALPS Medical Breakthroughs ETF (ARCA:SBIO)

Company Profile

AUM: US$81.58 million

Launched in December 2014, the ALPS Medical Breakthroughs ETF tracks small- and mid-cap biotech stocks that have one or more drugs in either Phase II or Phase III US FDA clinical trials. Its holdings must have a market cap between US$200 million and US$5 billion.

There are 104 holdings in this biotechnology fund, with about 90 percent being small- to mid-cap stocks. Its top holdings include Vaxcyte (NASDAQ:PCVX) at a weight of 3.98 percent, Immunovant (NASDAQ:IMVT) at 3.71 percent and Cerevel Therapeutics (NASDAQ:CERE), weighing 3.46 percent.

3. ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB)

Company Profile

AUM: US$70.74 million

ProShares Ultra NASDAQ Biotechnology ETF was launched in April 2010 and is leveraged to the broad-based NASDAQ Biotechnology Index. The ETF Database says BIB is ideal “for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies.”

The top biotech stocks in this ETF are Vertex Pharmaceuticals (NASDAQ:VRTX) at a 7.78 percent weight, Amgen (NASDAQ:AMGN) at a 7.47 percent weight and Gilead Sciences (NASDAQ:GILD) at 7.47 percent.

4. Principal Healthcare Innovators ETF (NASDAQ:BTEC)

Company Profile

AUM: US$39.1 million

The Principal Healthcare Innovators ETF tracks US-listed healthcare stocks with a focus on those researching and developing innovative medicines and therapies. This fund was first introduced to the market in August 2016 and invests at least 80 percent of its assets in mid- and small-cap companies.

There are 227 holdings in this biotechnology fund. Its top holdings are Seagen (NASDAQ:SGEN) at 4.45 percent, Exact Sciences (NASDAQ:EXAS) at 3.37 percent and Alnylam Pharmaceuticals (NASDAQ:ALNY) at a 3.26 percent weightage.

5. Virtus LifeSci Biotech Products ETF (ARCA:BBP)

Company Profile

AUM: US$14.31 million

Launched in December 2014, the Virtus LifeSci Biotech Products ETF tracks biotech companies that have completed multiple human clinical trials and have received US Food and Drug Administration approval to sell and market a drug.

There are 55 holdings in this biotechnology fund, with about 60 percent being mid- to large-cap stocks. Its top holdings include Intercept Pharmaceuticals (NASDAQ:ICPT) at a weight of 3.41 percent, BridgeBio Pharma (NASDAQ:BBIO) at a weight of 3.35 percent and Rhythm Pharmaceuticals (NASDAQ:RYTM) at 2.84 percent.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Cell Signaling Technology Leverages Integrated Cyber’s Employee-Focused Cybersecurity Service
next post
SensOre

Related Posts

Sage Potash Closes Private Placement of $1,822,500

May 28, 2024

Pilot Plant Commences First Phase of Operations

March 28, 2024

Lead Price Forecast: Top Trends That Will Affect...

December 28, 2023

Nuvau Minerals Inc. Changes Financial Year-End

March 1, 2025

Indicator Minerals in Gold Exploration (Updated 2024)

April 24, 2024

Biotech Market Forecast: Top Trends That Will Affect...

January 19, 2024

Barksdale is Drilling at Sunnyside

September 26, 2023

4 Factors That Drive Silver Demand (Updated 2023)

October 27, 2023

Canada Silver Cobalt Works

July 13, 2023

Lodgement of Bidder’s Statement

April 30, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • How I Triple My Returns With 3x Leveraged ETFs!

    • How to Find Compelling Charts in Every Sector

    • EVs Now Emit 73 percent Less Than Gasoline Cars Over Their Lifetime, Says ICCT Study

    • Cygnus Metals Limited: Issue of Performance Rights

    • FPX Nickel Announces Share-Based Compensation Grant

    • Blue Lagoon Resources Officially Opens Dome Mountain Gold Mine in British Columbia

    Categories

    • Business (1,287)
    • Investing (2,662)
    • Politics (3,699)
    • Stocks (1,711)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved